Sattari Sarvari Sogol, Rezaei Adriani Razieh, Nazarian Shahram, Fotouhi Arghavan, Mousavi Gargari Seyed Latif
Department of Biology, Shahed University, Tehran, Iran.
Department of Biology, Faculty of Science, Imam Hussein University, Tehran, Iran.
Iran Biomed J. 2025 Jan 1;29(1 & 2):36-48. doi: 10.61186/ibj.4933.
Brucella is a type of bacteria that causes a disease known as brucellosis in both humans and animals. Many different vaccine formulations are available for this disease; however, vaccines based on epitopes have shown to be effective, especially in combating this pathogen. In the present study, we designed a multi-epitope vaccine against brucellosis using a chimeric protein that combines segments from various Brucella proteins known to contain both B- and T-cell epitopes.
In this study, a vaccine candidate was developed using multiple epitopes derived from various proteins, including OMP31, TF, BLS, SOD, BP26, and L9. These epitopes were selected based on their high density of both B-cell and T-cell epitopes. The construct of the vaccine candidate was inserted into a pEGFP-N1 vector and introduced into HEK-293T cells. Subsequently, the vaccine was tested on different groups of mice; some received the expressed protein in E. coli, while others received the DNA vaccine candidate. An ELISA assay was employed to evaluate the humoral immune response.
Both the MEB protein (Pro/Pro) and pCI-MEB plasmid/MEB protein (DNA/Pro) groups showed a specific humoral response. The anti-DNA vaccine antibody titer did not rise as high as that of the protein groups; however, the observed protection indicated the efficiency of the DNA vaccine in activating the immune system.
While the chimeric DNA vaccine candidate induced a weaker humoral response, it remained effective in protecting against virulent strains of B. abortus and B. melitensis in the challenge route.
布鲁氏菌是一种可在人类和动物中引发布鲁氏菌病的细菌。针对这种疾病有多种不同的疫苗制剂；然而，基于表位的疫苗已显示出有效性，尤其是在对抗这种病原体方面。在本研究中，我们使用一种嵌合蛋白设计了一种针对布鲁氏菌病的多表位疫苗，该嵌合蛋白结合了已知包含B细胞和T细胞表位的各种布鲁氏菌蛋白的片段。
在本研究中，利用从包括OMP31、TF、BLS、SOD、BP26和L9等多种蛋白质中获得的多个表位开发了一种候选疫苗。这些表位是基于其高密度的B细胞和T细胞表位而选择的。将候选疫苗构建体插入pEGFP - N1载体并导入HEK - 293T细胞。随后，在不同组的小鼠上测试该疫苗；一些小鼠接受大肠杆菌中表达的蛋白，而另一些接受候选DNA疫苗。采用ELISA测定法评估体液免疫反应。
MEB蛋白（Pro/Pro）组和pCI - MEB质粒/MEB蛋白（DNA/Pro）组均显示出特异性体液反应。抗DNA疫苗抗体滴度没有蛋白组升得高；然而，观察到的保护作用表明DNA疫苗在激活免疫系统方面的有效性。
虽然候选嵌合DNA疫苗诱导出较弱的体液反应，但在攻毒途径中对流产布鲁氏菌和马尔他布鲁氏菌的强毒株仍具有有效的保护作用。
